Online inquiry

IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1102MR)

This product GTTS-WQ1102MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1102MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7516MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ2682MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ12976MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ15074MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ13273MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ6988MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ9791MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ10024MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW